NEW YORK (GenomeWeb) – Bio-Techne today announced a deal to buy protein analysis technology firm ProteinSimple for $300 million in cash.
ProteinSimple has appointed Joe Keegan and Chris van Ingen to its board of directors.
Keegan was previously the CEO of ForteBio and Molecular Devices.
Quanterix this week launched a commercial, research-use-only version of its Single Molecule Array, Simoa, platform.
ProteinSimple said this week that it has hired Terry Salyer as vice president of sales.
By Adam Bonislawski
A team led by Stanford University researchers has developed a method for predicting response to cancer therapies based on cellular signaling protein dynamics and changes in tumor size.
By a GenomeWeb staff reporter
CNN reports that researchers have tied a new variant to opioid addiction risk.
Organoids derived from patients' tumors may help determine what chemotherapy treatment patients would benefit from, according to New Scientist.
An initiative from GenomeAsia 100K hopes to increase the number of South Asians in genetic research, according to NBC News.
In Science this week: genomic analysis of ancient and modern horses indicates population turnover, and more.